print
Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer
- Source agency:
- LBI -HTA
- Date of Submission:
- 09/03/2010
- Date of Printing:
- 05/02/2012
- Technology name:
- Gefitinib, Iressa®
- Technology - type(s):
- Drug
- Patient indications:
- as first-line therapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR TK.